Author: Ashish Goyal; E. Fabian Cardozo-Ojeda; Joshua T Schiffer
Title: Potency and timing of antiviral therapy as determinants of duration of SARS CoV-2 shedding and intensity of inflammatory response Document date: 2020_4_14
ID: d7stppv5_62
Snippet: at 10mg/kg dose at day 0 and the plasma concentration of RDV and its active nucleoside triphosphate form in PBMCs were recorded over 24 hours. We digitize this data and employ it to fit PK model of RDV......
Document: at 10mg/kg dose at day 0 and the plasma concentration of RDV and its active nucleoside triphosphate form in PBMCs were recorded over 24 hours. We digitize this data and employ it to fit PK model of RDV.
Search related documents:
Co phrase search for related documents- 10mg kg dose and PK model: 1
- active nucleoside PBMCs triphosphate form and nucleoside PBMCs triphosphate form: 1, 2, 3
- active nucleoside PBMCs triphosphate form and PBMCs triphosphate form: 1, 2, 3
- active nucleoside PBMCs triphosphate form and PK model: 1
- active nucleoside PBMCs triphosphate form and plasma concentration: 1
- active nucleoside PBMCs triphosphate form and RDV PK model: 1
- active nucleoside PBMCs triphosphate form and triphosphate form: 1, 2, 3
- nucleoside PBMCs triphosphate form and PBMCs triphosphate form: 1, 2, 3
- nucleoside PBMCs triphosphate form and PK model: 1
- nucleoside PBMCs triphosphate form and plasma concentration: 1
- nucleoside PBMCs triphosphate form and RDV PK model: 1
- nucleoside PBMCs triphosphate form and triphosphate form: 1, 2, 3
- PBMCs triphosphate form and PK model: 1
- PBMCs triphosphate form and plasma concentration: 1
- PBMCs triphosphate form and RDV PK model: 1
- PBMCs triphosphate form and triphosphate form: 1, 2, 3
- PK model and plasma concentration: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
- PK model and RDV PK model: 1
- PK model and triphosphate form: 1
Co phrase search for related documents, hyperlinks ordered by date